Journal
ONCOTARGET
Volume 5, Issue 10, Pages 3023-3028Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.1814
Keywords
PARP inhibitors; off-target pharmacology; kinase profiling; drug combinations; biomarkers
Categories
Funding
- Catalan Government [2013FIB2-00073]
- Spanish Ministerio de Economia y Competitividad [BIO2011-26669]
Ask authors/readers for more resources
PARP inhibitors hold promise as a novel class of targeted anticancer drugs. However, their true mechanism of action is still not well understood following recent reports that show marked differences in cellular effects. Here, we demonstrate that three PARP drug candidates, namely, rucaparib, veliparib, and olaparib, have a clearly different in vitro affinity profile across a panel of diverse kinases selected using a computational approach that relates proteins by ligand similarity. In this respect, rucaparib inhibits nine kinases with micromolar affinity, including PIM1, PIM2, PRKD2, DYRK1A, CDK1, CDK9, HIPK2, CK2, and ALK. In contrast, olaparib does not inhibit any of the sixteen kinases tested. In between, veliparib inhibits only two, namely, PIM1 and CDK9. The differential kinase pharmacology observed among PARP inhibitors provides a plausible explanation to their different cellular effects and offers unexplored opportunities for this drug class, but alerts also on the risk associated to transferring directly both preclinical and clinical outcomes from one PARP drug candidate to another.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available